ORFI-OZ

ORFI-OZ Tablets is a broad-spectrum antimicrobial combination from Orfit Pharmaceutical Pvt. Ltd., formulated to effectively treat mixed bacterial and protozoal infections. It contains Ofloxacin 200 mg, a fluoroquinolone antibiotic, along with Ornidazole 500 mg, an antiprotozoal and anaerobic antibacterial agent, providing comprehensive coverage against a wide range of gastrointestinal and systemic infections. ORFI-OZ is commonly prescribed for the management of acute and chronic diarrhea, dysentery, gastroenteritis, amoebiasis, giardiasis, and other infections caused by susceptible bacteria and protozoa. Ofloxacin works by inhibiting bacterial DNA synthesis, leading to rapid bacterial elimination, while ornidazole targets anaerobic organisms and protozoa, ensuring complete and effective infection control. This combination helps achieve faster symptom relief, reduces the risk of recurrence, and improves overall treatment outcomes when used as directed by a healthcare professional. Manufactured under stringent quality and safety standards, ORFI-OZ reflects Orfit Pharmaceutical Pvt. Ltd.’s commitment to delivering reliable, effective, and clinically trusted antimicrobial solutions.